跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,877 条关于
“RELATIVITY-098”
全部
1,877
临床试验
1,098
药物
699
机构
9
资讯
71
去年
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial for LAG-3 Inhibitor
9个月前
GenSci Partners with RTW Investments in $1.365 Billion Deal for First-in-Class Thyroid Autoimmune Disease Therapy
2年前
Bristol Myers Squibb's Opdualag Shows Promise in Lung Cancer Phase 2 Trial
上个月
BMS Launches India's First LAG-3-Based Dual Immunotherapy for Metastatic Melanoma
去年
BRAF Status and Response Kinetics Guide First-line Immunotherapy Selection in Advanced Melanoma
2年前
ESMO Highlights: Imfinzi's Bladder Cancer Success, Keytruda/Lenvima Combo for Liver Cancer, and Opdualag's Lung Cancer Challenge
去年
Nivolumab/Relatlimab Combination Demonstrates Sustained Overall Survival Benefit in Advanced Melanoma
去年
Novel Immunotherapy Combinations Show Promise Beyond PD-1 Inhibition in Advanced NSCLC
去年
Sarilumab Combination Achieves 63.6% Response Rate in Advanced Melanoma Phase 2 Trial
去年
BMS's Opdualag Shows Strong Early Performance as First LAG-3 Checkpoint Inhibitor for Melanoma
第 1 页,共 8 页
上一页
下一页